A citation-based method for searching scientific literature

Mia Wadelius, Leslie Y Chen, Niclas Eriksson, Suzannah Bumpstead, Jilur Ghori, Claes Wadelius, David Bentley, Ralph McGinnis, Panos Deloukas. Hum Genet 2007
Times Cited: 288







List of co-cited articles
623 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Estimation of the warfarin dose with clinical and pharmacogenetic data.
T E Klein, R B Altman, N Eriksson, B F Gage, S E Kimmel, M-T M Lee, N A Limdi, D Page, D M Roden, M J Wagner,[...]. N Engl J Med 2009
43

A pharmacogenetic versus a clinical algorithm for warfarin dosing.
Stephen E Kimmel, Benjamin French, Scott E Kasner, Julie A Johnson, Jeffrey L Anderson, Brian F Gage, Yves D Rosenberg, Charles S Eby, Rosemary A Madigan, Robert B McBane,[...]. N Engl J Med 2013
526
28

A randomized trial of genotype-guided dosing of warfarin.
Munir Pirmohamed, Girvan Burnside, Niclas Eriksson, Andrea L Jorgensen, Cheng Hock Toh, Toby Nicholson, Patrick Kesteven, Christina Christersson, Bengt Wahlström, Christina Stafberg,[...]. N Engl J Med 2013
566
28

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
Elizabeth A Sconce, Tayyaba I Khan, Hilary A Wynne, Peter Avery, Louise Monkhouse, Barry P King, Peter Wood, Patrick Kesteven, Ann K Daly, Farhad Kamali. Blood 2005
681
27

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
Mark J Rieder, Alexander P Reiner, Brian F Gage, Deborah A Nickerson, Charles S Eby, Howard L McLeod, David K Blough, Kenneth E Thummel, David L Veenstra, Allan E Rettie. N Engl J Med 2005
27

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
B F Gage, C Eby, J A Johnson, E Deych, M J Rieder, P M Ridker, P E Milligan, G Grice, P Lenzini, A E Rettie,[...]. Clin Pharmacol Ther 2008
565
26

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, Chris Barnes, Niclas Eriksson, Nicole Soranzo, Pamela Whittaker, Venkatesh Ranganath, Vasudev Kumanduri, William McLaren,[...]. PLoS Genet 2009
461
26

The largest prospective warfarin-treated cohort supports genetic forecasting.
Mia Wadelius, Leslie Y Chen, Jonatan D Lindh, Niclas Eriksson, Mohammed J R Ghori, Suzannah Bumpstead, Lennart Holm, Ralph McGinnis, Anders Rane, Panos Deloukas. Blood 2009
409
23

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.
Giovanna D'Andrea, Rosa Lucia D'Ambrosio, Pasquale Di Perna, Massimiliano Chetta, Rosa Santacroce, Vincenzo Brancaccio, Elvira Grandone, Maurizio Margaglione. Blood 2005
543
19

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
Jeffrey L Anderson, Benjamin D Horne, Scott M Stevens, Amanda S Grove, Stephanie Barton, Zachery P Nicholas, Samera F S Kahn, Heidi T May, Kent M Samuelson, Joseph B Muhlestein,[...]. Circulation 2007
532
19

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
Gregory M Cooper, Julie A Johnson, Taimour Y Langaee, Hua Feng, Ian B Stanaway, Ute I Schwarz, Marylyn D Ritchie, C Michael Stein, Dan M Roden, Joshua D Smith,[...]. Blood 2008
319
17

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.
Hsiang-Yu Yuan, Jin-Jer Chen, M T Michael Lee, Ju-Chieh Wung, Ying-Fu Chen, Min-Ji Charng, Ming-Jen Lu, Chi-Ren Hung, Chun-Yu Wei, Chien-Hsiun Chen,[...]. Hum Mol Genet 2005
362
17

CYP4F2 genetic variant alters required warfarin dose.
Michael D Caldwell, Tarif Awad, Julie A Johnson, Brian F Gage, Mat Falkowski, Paul Gardina, Jason Hubbard, Yaron Turpaz, Taimour Y Langaee, Charles Eby,[...]. Blood 2008
389
16

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
Simone Rost, Andreas Fregin, Vytautas Ivaskevicius, Ernst Conzelmann, Konstanze Hörtnagel, Hans-Joachim Pelz, Knut Lappegard, Erhard Seifried, Inge Scharrer, Edward G D Tuddenham,[...]. Nature 2004
807
16

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
Minoli A Perera, Larisa H Cavallari, Nita A Limdi, Eric R Gamazon, Anuar Konkashbaev, Roxana Daneshjou, Anna Pluzhnikov, Dana C Crawford, Jelai Wang, Nianjun Liu,[...]. Lancet 2013
182
16

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Mitchell K Higashi, David L Veenstra, L Midori Kondo, Ann K Wittkowsky, Sengkeo L Srinouanprachanh, Fred M Farin, Allan E Rettie. JAMA 2002
791
16

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.
Brian F Gage, Charles Eby, Paul E Milligan, Gerald A Banet, Jill R Duncan, Howard L McLeod. Thromb Haemost 2004
256
15

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
J A Johnson, L Gong, M Whirl-Carrillo, B F Gage, S A Scott, C M Stein, J L Anderson, S E Kimmel, M T M Lee, M Pirmohamed,[...]. Clin Pharmacol Ther 2011
437
15

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Nita A Limdi, Mia Wadelius, Larisa Cavallari, Niclas Eriksson, Dana C Crawford, Ming-Ta M Lee, Chien-Hsiun Chen, Alison Motsinger-Reif, Hersh Sagreiya, Nianjun Liu,[...]. Blood 2010
268
13

Common VKORC1 and GGCX polymorphisms associated with warfarin dose.
M Wadelius, L Y Chen, K Downes, J Ghori, S Hunt, N Eriksson, O Wallerman, H Melhus, C Wadelius, D Bentley,[...]. Pharmacogenomics J 2005
366
12

Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients.
Sheng-Wen Huang, Hai-Sheng Chen, Xian-Qun Wang, Ling Huang, Ding-Li Xu, Xiao-Jia Hu, Zhi-Hui Huang, Yong He, Kai-Ming Chen, Dao-Kang Xiang,[...]. Pharmacogenet Genomics 2009
125
12

Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes.
Yusheng Zhu, Michael Shennan, Kristen K Reynolds, Nancy A Johnson, Matthew R Herrnberger, Roland Valdes, Mark W Linder. Clin Chem 2007
160
12

Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
Mohamed Hossam A Shahin, Sherief I Khalifa, Yan Gong, Lamiaa N Hammad, Mohamed T H Sallam, Mostafa El Shafey, Shawky S Ali, Mohamed-Eslam F Mohamed, Taimour Langaee, Julie A Johnson. Pharmacogenet Genomics 2011
74
16

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
J A Johnson, K E Caudle, L Gong, M Whirl-Carrillo, C M Stein, S A Scott, M T Lee, B F Gage, S E Kimmel, M A Perera,[...]. Clin Pharmacol Ther 2017
298
12


Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
Farhad Kamali, Tayyaba Irfan Khan, Barry P King, Richard Frearson, Patrick Kesteven, Peter Wood, Ann K Daly, Hilary Wynne. Clin Pharmacol Ther 2004
175
11

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.
J Hirsh, J Dalen, D R Anderson, L Poller, H Bussey, J Ansell, D Deykin. Chest 2001
696
10

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.
Laurent Bodin, Céline Verstuyft, David-Alexandre Tregouet, Annie Robert, Liliane Dubert, Christian Funck-Brentano, Patrice Jaillon, Philippe Beaune, Pierre Laurent-Puig, Laurent Becquemont,[...]. Blood 2005
287
10

Human P450 metabolism of warfarin.
L S Kaminsky, Z Y Zhang. Pharmacol Ther 1997
609
10

Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese.
Pei-Chieng Cha, Taisei Mushiroda, Atsushi Takahashi, Michiaki Kubo, Shiro Minami, Naoyuki Kamatani, Yusuke Nakamura. Hum Mol Genet 2010
104
10

Integration of genetic, clinical, and INR data to refine warfarin dosing.
P Lenzini, M Wadelius, S Kimmel, J L Anderson, A L Jorgensen, M Pirmohamed, M D Caldwell, N Limdi, J K Burmester, M B Dowd,[...]. Clin Pharmacol Ther 2010
170
10

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.
Matthew G McDonald, Mark J Rieder, Mariko Nakano, Clara K Hsia, Allan E Rettie. Mol Pharmacol 2009
219
10

Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
Brian F Gage, Anne R Bass, Hannah Lin, Scott C Woller, Scott M Stevens, Noor Al-Hammadi, Juan Li, Tomás Rodríguez, J Philip Miller, Gwendolyn A McMillin,[...]. JAMA 2017
144
10

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.
Jonatan D Lindh, Lennart Holm, Marine L Andersson, Anders Rane. Eur J Clin Pharmacol 2009
159
9

Identification of the gene for vitamin K epoxide reductase.
Tao Li, Chun-Yun Chang, Da-Yun Jin, Pen-Jen Lin, Anastasia Khvorova, Darrel W Stafford. Nature 2004
497
9

Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.
M-S Wen, Mtm Lee, J-J Chen, H-P Chuang, L-S Lu, C-H Chen, T-H Lee, C-T Kuo, F-M Sun, Y-J Chang,[...]. Clin Pharmacol Ther 2008
117
9


Pharmacogenetics of warfarin: current status and future challenges.
M Wadelius, M Pirmohamed. Pharmacogenomics J 2007
226
9

Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans.
Adam Bress, Shitalben R Patel, Minoli A Perera, Richard T Campbell, Rick A Kittles, Larisa H Cavallari. Pharmacogenomics 2012
47
19

Warfarin pharmacogenetics.
Julie A Johnson, Larisa H Cavallari. Trends Cardiovasc Med 2015
89
10

Genetic and clinical predictors of warfarin dose requirements in African Americans.
L H Cavallari, T Y Langaee, K M Momary, N L Shapiro, E A Nutescu, W A Coty, M A G Viana, S R Patel, J A Johnson. Clin Pharmacol Ther 2010
148
9

Systematic overview of warfarin and its drug and food interactions.
Anne M Holbrook, Jennifer A Pereira, Renee Labiris, Heather McDonald, James D Douketis, Mark Crowther, Philip S Wells. Arch Intern Med 2005
718
9

A method to determine the optimal intensity of oral anticoagulant therapy.
F R Rosendaal, S C Cannegieter, F J van der Meer, E Briët. Thromb Haemost 1993
9

A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms.
Michela Cini, Cristina Legnani, Benilde Cosmi, Giuliana Guazzaloca, Lelia Valdrè, Mirella Frascaro, Gualtiero Palareti. Eur J Clin Pharmacol 2012
29
27

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.
Lai-San Tham, Boon-Cher Goh, Anne Nafziger, Jia-Yi Guo, Ling-Zhi Wang, Richie Soong, Soo-Chin Lee. Clin Pharmacol Ther 2006
124
8

Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Alan H B Wu, Ping Wang, Andrew Smith, Christine Haller, Katherine Drake, Mark Linder, Roland Valdes. Pharmacogenomics 2008
129
8


Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
John F Carlquist, Benjamin D Horne, Joseph B Muhlestein, Donald L Lappé, Bryant M Whiting, Matthew J Kolek, Jessica L Clarke, Brent C James, Jeffrey L Anderson. J Thromb Thrombolysis 2006
174
8

Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial.
MingSong Wang, XiLong Lang, ShiTao Cui, Ke Fei, LiangJian Zou, Jia Cao, LiangXu Wang, ShengHui Zhang, XinTian Wu, YiLing Wang,[...]. Int J Med Sci 2012
41
19

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.
Michael A Hillman, Russell A Wilke, Steven H Yale, Humberto J Vidaillet, Michael D Caldwell, Ingrid Glurich, Richard L Berg, John Schmelzer, James K Burmester. Clin Med Res 2005
159
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.